Abivax’s investigational oral miRNA-enhancer drug obefazimod demonstrated compelling clinical remission in two Phase 3 trials involving moderately to severely active ulcerative colitis patients who were inadequately managed by prior treatments. The trials reported a pooled 16.4% placebo-adjusted remission rate and significant clinical response. Abivax intends to complete a 44-week maintenance study with results expected in 2026, positioning obefazimod as a potential first-in-class therapeutic with robust efficacy and safety. Positive market reactions followed, reflecting optimism in a highly competitive inflammatory bowel disease market.